Ori Biotech and Vineti have announced a strategic partnership to produce pre-integrated solutions to fast-track and streamline the manufacture and delivery of cell and gene therapies (CGTs).
The two companies will enter into a non-exclusive partnership to help develop systems to aid the production of CGTs, providing infrastructure and technology solutions for therapy developers, contract manufacturers, and academic centres.
Ori Biotech CEO, Jason C. Foster, said: “The pre-integration of Vineti’s Chain of Identity and Chain of Custody systems with the Ori full-stack platform is critical to help ensure our customers have full end-to-end visibility, control, and insights into their processes.
“The addition of established technologies in such a critical aspect of CGT manufacturing allows us to enable our partners across the industry to develop and commercialise therapies as safely, cost effectively, and quickly as possible to reach the large numbers of patients who need these therapeutic alternatives.”
Ori Biotech is a London and New Jersey based CGT manufacturing technology company, and has developed a manufacturing platform that closes, automates, and standardises CGT manufacturing. This platform allows therapeutics developers to further develop and bring their products to market at commercial scale.
Vineti was co-founded by GE and the Mayo Clinic, and also offers a digital platform, one of record to integrate logistics, supply chain management, manufacturing, and clinical data for personalised therapies.
The platform aligns and orchestrates the advanced therapy process and improves product performance overall, supporting the continuum of patient-specific therapies, including personalised cancer vaccines and autologous and allogeneic cell and gene therapies.
Amy DuRoss, Vineti CEO and Co-founder, said: “Advanced therapies are at a point where they require true industrialisation, with the best digital tools and a connected ecosystem. We’re very excited to partner with Ori Biotech to deliver our shared next-generation vision and ultimately help breakthrough treatments get to patients faster.”
Kat Jenkins
This is a syndicated feed from Pharmafile
